Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Equities researchers at Zacks Research lowered their FY2025 earnings per share (EPS) estimates for shares of Amicus Therapeutics in a research report issued on Thursday, January 30th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of $0.09 per share for the year, down from their prior forecast of $0.14. The consensus estimate for Amicus Therapeutics' current full-year earnings is ($0.04) per share. Zacks Research also issued estimates for Amicus Therapeutics' Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.09 EPS and FY2026 earnings at $0.24 EPS.
A number of other equities research analysts have also weighed in on FOLD. Guggenheim boosted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Cantor Fitzgerald restated an "overweight" rating and issued a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. JPMorgan Chase & Co. increased their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a research report on Tuesday, November 12th. Morgan Stanley restated an "equal weight" rating and issued a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Finally, StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Amicus Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.88.
Read Our Latest Analysis on Amicus Therapeutics
Amicus Therapeutics Trading Up 0.5 %
Shares of FOLD stock traded up $0.05 on Monday, hitting $9.83. 2,385,274 shares of the company's stock traded hands, compared to its average volume of 2,104,174. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The stock has a market capitalization of $2.94 billion, a price-to-earnings ratio of -28.91, a P/E/G ratio of 1.65 and a beta of 0.61. The company's fifty day simple moving average is $9.63 and its 200 day simple moving average is $10.45. Amicus Therapeutics has a one year low of $8.78 and a one year high of $14.03.
Insiders Place Their Bets
In related news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,884,273.08. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.20% of the company's stock.
Institutional Investors Weigh In On Amicus Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the business. Hazlett Burt & Watson Inc. grew its stake in shares of Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 1,569 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Amicus Therapeutics by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company's stock worth $115,000 after acquiring an additional 1,884 shares in the last quarter. OLD Second National Bank of Aurora purchased a new stake in shares of Amicus Therapeutics in the third quarter worth $26,000. AlphaCentric Advisors LLC increased its holdings in shares of Amicus Therapeutics by 1.2% during the third quarter. AlphaCentric Advisors LLC now owns 205,000 shares of the biopharmaceutical company's stock valued at $2,189,000 after acquiring an additional 2,500 shares in the last quarter. Finally, Diversified Trust Co raised its position in shares of Amicus Therapeutics by 3.8% in the 3rd quarter. Diversified Trust Co now owns 74,501 shares of the biopharmaceutical company's stock worth $796,000 after purchasing an additional 2,698 shares during the last quarter.
About Amicus Therapeutics
(
Get Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Further Reading
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
